Related Experiment Video
Updated: Mar 12, 2026
07:43
Author Spotlight: Exploring Advanced Therapeutic Targets in Osteosarcoma Through Spatial Transcriptomics
Published on: May 3, 2024
4.7K
Diagnostic accuracy of CD44V6 for osteosarcoma: a meta-analysis
Yunyuan Zhang1, Limin Lun1, Baozhi Zhu1
1Department of Clinical Laboratory, The Affiliated Hospital of Qingdao University, Qingdao, 266003, People's Republic of China.
Journal of Orthopaedic Surgery and Research
|November 5, 2016
Summary
CD44V6 expression is linked to osteosarcoma (OS). This meta-analysis suggests CD44V6 may serve as a valuable diagnostic biomarker for OS, aiding in distinguishing it from benign conditions.
Area of Science:
- Oncology
- Biomarker Discovery
- Diagnostic Accuracy
Background:
- Emerging evidence suggests a link between CD44V6 and osteosarcoma (OS).
- The clinical utility of CD44V6 as a diagnostic biomarker for OS remains to be established.
- This study aims to evaluate the diagnostic performance of CD44V6 in OS.
Purpose of the Study:
- To assess the diagnostic value of CD44V6 in osteosarcoma (OS).
- To conduct a meta-analysis of existing literature on CD44V6 and OS diagnosis.
Main Methods:
- A comprehensive literature search was conducted across multiple international and Chinese databases up to April 2016.
- Eligible studies were selected, and their quality was assessed using QUADAS.
- Data extraction and statistical analyses were performed using STATA 12 and Meta-DiSc 1.4.
Main Results:
- Eight studies comprising 463 cases and 188 controls were included.
- The area under the receiver operating characteristic curve (AUC) was 0.91, indicating good diagnostic performance.
- Pooled sensitivity was 0.743 and specificity was 0.897, with significant heterogeneity observed (I²=90%).
Conclusions:
- Elevated CD44V6 expression levels are associated with osteosarcoma.
- CD44V6 demonstrates potential as a diagnostic marker for osteosarcoma.
- Further research may validate its role in clinical settings.
